

Mammacheck – Liquid Biopsy Breast Cancer Test

Urine-based miRNA Diagnostics

Technology

Breast cancer (BC) is the most common type of cancer in many countries. About 1 in 7 women are diagnosed with breast cancer during their lifetime. One third of the patients are under the age of 55. Early detection of BC is the decisive factor for the cure rate. Non-invasive liquid biomarkers allow early diagnosis, which increases the chance for successful treatment dramatically.

We present a patient-friendly PCR based-breast cancer test with sensitivity and specificity of above 70%. The test is based on isolation of miRs from exosomes in urine samples. Expression analysis of these nucleic acids provides distinct characteristic pattern to distinguish cancer patients from healthy controls. Especially younger women below the age of 50 can profit from this test as assay performance is particularly high in this group.

Innovation

- Sensitive and specific breast cancer test
- Superior to current diagnostic methods (palpation, mammography)
- Patient friendly liquid biopsy
- Quantification of circulating microRNA in urine

Application

- All women, preferably of ages under 50
- Easy accessibility, high acceptability
- Potential for routine testing

Responsible Scientist

Prof. Dr. Thalia Erbes
Institute of Gynecology,
University of Freiburg
Now: Diako Mannheim

Patent Status

Granted Patents:
EP3772543, EP4010498

Pending patents:
US, AU, KR

Earliest Priority Date

09.08.2019

Reference Number

2018102904/ZEE

Status: Nov-24



CTF – The R&D Company of the
Freiburg University and the Freiburg
University Medical Center

universität freiburg

Contact

Dr. Markus Schwab
Campus Technologies Freiburg GmbH
Stefan-Meier-Str. 8 | D-79104 Freiburg
Email: markus.schwab@campus-technologies.de
Tel: +49 (0)761 203-4987
Fax: +49 (0)761 203-5021